Endpoints News 12. Jan. 2026 Eisai licenses Nuvation lung cancer pill; Alnylam's stock dips after sales data report
Endpoints News 12. Jan. 2026 AbbVie jumps into PD-1xVEGF bispecific race, pays $650M upfront to RemeGen
Endpoints News 12. Jan. 2026 FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus
Endpoints News 12. Jan. 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Endpoints News 10. Jan. 2026 US slashes vaccine schedule; Every drug approval from 2025; argenx’s new CEO; and more